Substandard and falsified medications pose significant risks to global health. Nearly one in five antimalarials circulating in low- and middle-income countries are substandard or falsified. We assessed the health and economic impact of substandard and falsified antimalarials on children under five in Nigeria, where malaria is endemic and poor-quality medications are commonplace.
To tackle one of the most urgent public health crises facing the world today – antimicrobial resistance (AMR) – universal health coverage (UHC) must be realized. It’s time to take action by ensuring that everyone has access to safe, effective, quality-assured medicines.
Evolution of Rifampin resistance in Escherichia coli and Mycobacterium smegmatis due to substandard drugs
Poor-quality medicines undermine the treatment of infectious diseases, such as tuberculosis, which require months of treatment with rifampin and other drugs.
This Thursday (25 April) is World Malaria Day and we hope you’ll join us in calling for #MedsWeCanTrust. If you or your organization would be willing to share social media content on this topic, please see our #WorldMalariaDay social media toolkit for suggested language and graphics.
Artemisinin-based combination therapies are the frontline treatment of Plasmodium falciparum malaria.
In response to the growing AMR crisis, the UN Interagency Coordination Group on Antimicrobial Resistance (IACG) – which was created following the UN High-Level Meeting on AMR in 2016 – released its seminal report with recommendations on how to curb the spread of AMR.
The selection and spread of antimalarial drug resistance pose enormous challenges to the health of people living in tropical countries.
Falciparum malaria kills, and it particularly kills the rural poor. Artemisinin derivatives, such as artesunate, are a vital component of Plasmodium falciparum malaria treatment and control in the face of globally increasing antimalarial drug resistance.